GlobeNewswire

New Research Reveals Majority of Recruiters Ready for GDPR; Concerns Remain About Sourcing and Hiring Under New Guidelines

Dela

Data from Lever Examines How Organizations are Preparing for GDPR Compliance Specific to Recruiting and Hiring

 

SAN FRANCISCO, March 27, 2018 (GLOBE NEWSWIRE) -- While nearly three quarters of organizations feel confident in their ability to achieve General Data Protection Regulation (GDPR) compliance for their recruiting efforts by the May 25th deadline, most still harbor concerns about how the new regulations will impact their hiring process, according to new research from Lever, the recruiting software for more than 1,500 leading companies around the world. Lever surveyed 500 professionals across the EU and US directly involved in preparing their organizations for GDPR compliance for recruiting.

According to the survey results, 70 percent of respondents believe they will be prepared for GDPR compliant recruiting by May 25th, but preparation doesn't come overnight, or in a silo. Nearly a third of respondents say they are investing significant time and resources into becoming GDPR compliant and 73 percent are working with external or internal legal counsel to prepare.

Despite this high level of preparedness, 61 percent of respondents are concerned about the impact of GDPR on their recruiting and hiring processes, including how they source potential candidates. Respondents were also either 'very concerned' or 'extremely concerned' about adhering to specific requirements included in the regulations, such as:

  • Maintaining full records of recruiting processing activities (52 percent)
  • Determining when to get consent from candidates (50 percent)
  • Determining how long to store a candidate's personal data before deleting it or obtaining consent (47 percent)
  • Selecting software vendors who will enter into GDPR compliant contracts and meet data security requirements (46 percent)

Regardless of these concerns, the overwhelming majority (90 percent) of respondents who are already engaged in sourcing will continue to do so under GDPR.

"The GDPR deadline is quickly approaching, but few are discussing the potential impact these regulations will have on how organizations source, recruit and hire their talent," said Mike Walsh, Director of Product Marketing of Lever. "We hope this research serves as a catalyst within organizations to begin discussing in detail how they will move forward with sourcing candidates under GDPR and the lengths they will go to protect candidate data. At Lever, we have spent significant time working on these issues on behalf of our clients and hope to continue to serve as a resource for recruiters worldwide."

Lever's research also revealed some organizations are unsure how to adhere to regulations related to candidate data. According to the GDPR, organizations must identify their own "lawful basis" for processing personal candidate data. For recruiting, the most common lawful bases are consent and legitimate interest, but it can be a grey area for many recruiters.

For example, respondents are split regarding when to collect consent from candidates. Only 40 percent of respondents will collect consent to contact for jobs they did not apply to, 37 percent will collect consent in order to email candidates they source and 25.5 percent will collect consent when they plan to keep data from candidates who were in their ATS before May 25th, 2018.

Another grey area the survey addressed was determining how long to store candidate data. While GDPR requires companies to only keep personal data for "no longer than is necessary for the purposes for which the personal data are processed," the data showed great variation in how organizations are interpreting this obligation. Some companies will delete candidate data as soon as the job they were tied to closes (23 percent), while others plan to retain candidate data for a year or more (23 percent).

The full research report can be downloaded at this link.

Methodology
From March 2 - 8, 2018, Lever surveyed 500 professionals across the EU and US who are directly involved in preparing their organizations for GDPR compliance for recruiting.

About Lever
Built from the conviction that recruiting is the responsibility of everyone at the company, Lever's applicant tracking and sourcing technology draws the entire team together to source, nurture, interview, and hire top talent through effortless collaboration. Lever has been intentionally designed with integrated ATS and CRM functionality, and features a modern interface that helps employers develop stronger candidate relationships in fewer clicks. 

Lever was founded in 2012 in San Francisco. The company has raised more than $73 million in funding from Adams Street Partners, Scale Venture Partners, Matrix Partners, Y Combinator, Redpoint Ventures, and Correlation Ventures among others. Lever supports the hiring needs of over 1,500 companies around the globe including the teams at Netflix, Hot Topic, KPMG New Zealand, and Cirque du Soleil. With an overall gender ratio of 50:50, Lever is also fiercely committed to building a team culture that celebrates diversity and inclusion. For more information, visit https://www.lever.co.

MEDIA CONTACT:
Ashley Cohen
Traeger Communications
acohen@traegercommunications.com
303-522-0783




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lever, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum